Teva (TEVA) confident that process towards biogenerics momentum will grow

Written by: Zack Miller | November 15, 2007

I stumbled across the Reuters Health Summit that’s taking place in New York this week. Interestingly enough, they’re blogging the conference, so cheap investors like me can “attend” remotely. You can find the blog for the summit here.

Israeli generics giant, Teva Pharmaceuticals (Nasdaq: TEVA), participated and there’s a great (short) audio clip on what Teva believes in happening in the biogenerics space during and after the election cycle. Go here to check it out.

Related posts

Category: Teva, biotech, israel, pharma
Tags: , , , , ,
Email Email  Print This Post Print This Post

2 Comments »

Pingback by EPIX Pharmaceuticals(EPIX): Hey Ma Look What I Found | Israel Opportunity Investor on December 21, 2007

[...] is huge. Consider as well, with an aging population this could be absolutely huge for the little Biotech company with a market-cap of just $141 million. After seeing the stock surge more than 50% on the [...]

Pingback by TEVA's Parkinson's Breakthrough | Israel Opportunity Investor on June 17, 2008

[...] Teva, this drug has the potential to generate $1billion is sales, and be a mega-drug. Teva, biggest generic drug company in the world, has also turned into a R&D powerhouse focusing on [...]

Leave a comment